Key result
Roux-en-Y gastric bypass significantly reduced lipoprotein(a) by an additional 8.5 nmol/L and non-HDL cholesterol by 0.52 mmol/L compared to sleeve gastrectomy at 6 to 12 months postoperatively.
Why the study?
The efficacy of different bariatric procedures on obese dyslipidemia remains debated, and their impact on Lp(a) levels is unknown.
Does gastric bypass (RYGB) improve non-HDL cholesterol, LDL/HDL-ratio, and Lp(a) levels more than sleeve gastrectomy (SG) in adult patients with morbid obesity?
Cohort (n=111)
No
Does gastric bypass (RYGB) improve non-HDL cholesterol, LDL/HDL-ratio, and Lp(a) levels more than sleeve gastrectomy (SG) in adult patients with morbid obesity?
Roux-en-Y gastric bypass is more effective than sleeve gastrectomy at improving dyslipidemia, including lowering Lp(a), in patients with morbid obesity.
May favor RYGB for lipid management in obesity; hypothesis-generating and requires randomized confirmation.
The efficacy of various bariatric procedures on the mitigation of the obese dyslipidemia remains debated, and the impact of these measures on lipoprotein(a) (Lp(a)) levels is unknown. In this study we aimed to compare the two most commonly used procedures: gastric bypass (RYGB) and sleeve gastrectomy (SG). Adult patients with morbid obesity were assigned to receive either RYGB or SG. The levels of non-HDL cholesterol, LDL/HDL-ratio and Lp(a) at examinations conducted 6 and 12 months postoperatively were determined and compared to preoperative levels to estimate the efficacy of the two surgical methods. All results 6 and 12 months after surgery were used in the comparisons with the preoperative results. A linear mixed regression model for repeated analyses was used. The Lp(a) and the non-HDL cholesterol levels were considerably reduced in the RYGB group, in contrast to the minor changes in the SG group. In addition, the LDL/HDL ratio was significantly more reduced in the RYGB group when compared to the SG group. Conclusively, RYGB was found to be more efficient than SG for the mitigation of obese dyslipidemia, including preoperative high Lp(a)-levels. This might have important individual and societal implications, especially regarding the potential to reduce the risk of cardiovascular disease and the related societal costs.
No takes yet. Share an insight, caveat, or question.
Aaseth et al. (2022) conducted a cohort in Morbid obesity (n=111). Roux-en-Y gastric bypass (RYGB) vs. Sleeve gastrectomy (SG) was evaluated on Change in lipoprotein(a) levels (nmol/L) (MD -8.5, 95% CI -17.0 to -0.04, p=0.049). Roux-en-Y gastric bypass significantly reduced lipoprotein(a) by an additional 8.5 nmol/L and non-HDL cholesterol by 0.52 mmol/L compared to sleeve gastrectomy at 6 to 12 months postoperatively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: